We hypothesized that this combination would be similarly effective in neuroblastoma with hyperactivity of the RAS/MAPK pathway, either through mutation of one of the RAS isoforms or through inactivation of the RAS GTPase activating protein, NF1. This evidence concerns the gene RASA2 and neuroblastoma.